Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Staphylococcus aureus bacteremia in children: Management and outcome

Sheldon L Kaplan, MD
Section Editor
Morven S Edwards, MD
Deputy Editor
Carrie Armsby, MD, MPH


Staphylococcus aureus is a leading cause of both community-associated and hospital-acquired bacteremia. S. aureus bacteremia (SAB) is associated with increased morbidity and mortality, even with appropriate therapy.

The treatment and outcome of S. aureus bacteremia in children are reviewed here. The epidemiology and clinical manifestations of S. aureus bacteremia in children are discussed separately. (See "Staphylococcus aureus bacteremia in children: Epidemiology and clinical features".)


Supportive care — Supportive measures for children with S. aureus bacteremia (SAB) may include:

Fever management

Respiratory support for patients with pneumonia or respiratory distress (see "Oxygen monitoring and therapy in the newborn")


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Feb 2017. | This topic last updated: Thu Jun 23 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21:910.
  2. Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33:990.
  3. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40:1785.
  4. Gonzalez BE, Rueda AM, Shelburne SA 3rd, et al. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 2006; 27:1051.
  5. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647.
  6. Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46:1147.
  7. Szczesiul JM, Shermock KM, Murtaza UI, Siberry GK. No decrease in clindamycin susceptibility despite increased use of clindamycin for pediatric community-associated methicillin-resistant Staphylococcus aureus skin infections. Pediatr Infect Dis J 2007; 26:852.
  8. McGehee RF R, Barre FF, Finland M. Resistance of Staphylococcus aureus to lincomycin, clinimycin, and erythromycin. Antimicrob Agents Chemother (Bethesda) 1968; 8:392.
  9. Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 1999; 44:581.
  10. Drinkovic D, Fuller ER, Shore KP, et al. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001; 48:315.
  11. Jenssen WD, Thakker-Varia S, Dubin DT, Weinstein MP. Prevalence of macrolides-lincosamides-streptogramin B resistance and erm gene classes among clinical strains of staphylococci and streptococci. Antimicrob Agents Chemother 1987; 31:883.
  12. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003; 41:4740.
  13. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257.
  14. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530.
  15. Martínez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.
  16. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.
  17. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275.
  18. McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158:422.
  19. Moffett BS, Kim S, Edwards M. Vancomycin nephrotoxicity may be overstated. J Pediatr 2011; 158:865.
  20. Cies JJ, Shankar V. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit. Pharmacotherapy 2013; 33:392.
  21. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J 2013; 32:1077.
  22. Chhim RF, Arnold SR, Lee KR. Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children wtih suspected invasive staphylococcal infections. J Pediatric Infect Dis Soc 2013; 2:259.
  23. McNeil JC, Kok EY, Forbes AR, et al. Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome. Pediatr Infect Dis J 2016; 35:263.
  24. González C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171.
  25. Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179:1157.
  26. McDanel JS, Perencevich EN, Diekema DJ, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis 2015; 61:361.
  27. Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805.
  28. Spencer DH, Sellenriek P, Burnham CA. Validation and implementation of the GeneXpert MRSA/SA blood culture assay in a pediatric setting. Am J Clin Pathol 2011; 136:690.
  29. Tetzlaff TR, McCracken GH Jr, Nelson JD. Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis. J Pediatr 1978; 92:485.
  30. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.
  31. Carrillo-Marquez MA, Hulten KG, Mason EO, Kaplan SL. Clinical and molecular epidemiology of Staphylococcus aureus catheter-related bacteremia in children. Pediatr Infect Dis J 2010; 29:410.
  32. Rubin LG, Shih S, Shende A, et al. Cure of implantable venous port-associated bloodstream infections in pediatric hematology-oncology patients without catheter removal. Clin Infect Dis 1999; 29:102.
  33. American Academy of Pediatrics. Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.715.
  34. Suryati BA, Watson M. Staphylococcus aureus bacteraemia in children: a 5-year retrospective review. J Paediatr Child Health 2002; 38:290.
  35. Friedland IR, du Plessis J, Cilliers A. Cardiac complications in children with Staphylococcus aureus bacteremia. J Pediatr 1995; 127:746.
  36. Hill PC, Wong CG, Voss LM, et al. Prospective study of 125 cases of Staphylococcus aureus bacteremia in children in New Zealand. Pediatr Infect Dis J 2001; 20:868.
  37. McNeil JC, Ligon JA, Hulten KG, et al. Staphylococcus aureus Infections in Children With Congenital Heart Disease. J Pediatric Infect Dis Soc 2013; 2:337.
  38. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353:1245.
  39. Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005; 115:642.
  40. Skinner, D, Keefer, CS. Significance of bacteremia caused by Staphylococcus aureus: A study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Arch Intern Med 1941; 68:851.
  41. Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695.
  42. Frederiksen MS, Espersen F, Frimodt-Møller N, et al. Changing epidemiology of pediatric Staphylococcus aureus bacteremia in Denmark from 1971 through 2000. Pediatr Infect Dis J 2007; 26:398.
  43. Asgeirsson H, Gudlaugsson O, Kristinsson KG, et al. Low mortality of Staphylococcus aureus bacteremia in Icelandic children: nationwide study on incidence and outcome. Pediatr Infect Dis J 2015; 34:140.
  44. Cobos-Carrascosa E, Soler-Palacín P, Nieves Larrosa M, et al. Staphylococcus aureus Bacteremia in Children: Changes During Eighteen Years. Pediatr Infect Dis J 2015; 34:1329.
  45. Valente AM, Jain R, Scheurer M, et al. Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia. Pediatrics 2005; 115:e15.
  46. Welsh KJ, Abbott AN, Lewis EM, et al. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J Clin Microbiol 2010; 48:894.